New hope for Hard-to-Treat breast cancer: experimental drug MR001 enters human trials
NCT ID NCT07208149
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called MR001 in people with advanced triple-negative breast cancer (TNBC) whose cancer has worsened after standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 42 participants will receive MR001 in a clinic setting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can a Custom-Made vaccine outsmart Triple-Negative breast cancer?
- Can a drug combo outsmart a tough breast cancer subtype?
- Can a new drug combo outsmart triple-negative breast cancer?
- Can your own immune cells fight advanced cancer?
- Can a biomarker spare breast cancer patients from harsh chemo?